Dr O’Mahony is currently Vice President of Research Biology at Eurofins DiscoverX leading the scientific application of their proprietary BioMAP® platform to fundamentally improve the productivity and efficacy of drug development. As head of R&D, Alison has lead efforts on the development, validation and utilization of BioMAP systems in the areas of autoimmunity, inflammation, fibrosis, immune oncology, tissue remodeling etc. Prior to joining the BioMAP team, Dr O’Mahony was an Investigator at the Gladstone Institutes at UCSF and has over 25 years specializing in cell biology, signal transduction and biomarker expression.

She has considerable expertise and experience in phenotypic primary human cell-based systems as predictive models for drug discovery. Dr O’Mahony holds a Ph.D. from the National University of Ireland and was a postdoctoral fellow at University of California, Davis and at UCSF. She has published multiple peer-reviewed papers and invited book chapters and has received a number of international and national awards for her work.

Prof. Harrington specialises in developing new treatments using biologically targeted agents (such as viruses, antibodies and small molecules) that selectively destroy cancer cells. He is Professor of Biological Cancer Therapies at The Institute of Cancer Research and an honorary consultant oncologist at The Royal Marsden.

He was appointed as Joint Head of the ICR’s Division of Radiotherapy and Imaging in 2013. Prof. Harrington studied medicine at St Bartholomew’s Hospital, London, and began focusing on head and neck cancer while a PhD student at Hammersmith Hospital. He completed postdoctoral research in molecular medicine at the Mayo Clinic, Minnesota, before joining the ICR in 2001 as Team Leader in Targeted Therapy within the Section of Cell and Molecular Biology.

Dr Goggins is a professor of pathology, medicine and oncology at the Johns Hopkins University School of Medicine. He serves as director of the Pancreatic Cancer Early Detection Laboratory and is an attending physician in medicine in the Division of Gastroenterology and Hepatology at The Johns Hopkins Hospital, as well as a molecular biologist.

Dr. Goggins’ research interests include the role of germline BRCA2 mutations in pancreas cancer and characterizing the molecular genetic progression model for pancreas cancer. He obtained his medical degree in 1988 from Trinity College of the University of Dublin, Ireland. He completed a residency in internal medicine and a fellowship in Gastroenterology at St. James’ Hospital in Dublin. He obtained his Membership of the Royal College of Physicians of Ireland in 1991 and his European Diploma in Gastroenterology in 1995. He joined the Johns Hopkins faculty in 1999.

Dr. Goggins is a member of the Royal College of Physicians and the European Board of Gastroenterology. He sits on the editorial boards of Gut, Clinical Gastroenterology and Hepatology, and Cancer Biology and Therapy.

Dr. O’Connor is an international authority in lymphoma and drug development, with more than 25 years of experience in academic medicine. He is Chief Scientific Officer of TG Therapeutics. Dr. O’Connor is widely recognized for his contributions to the field, having pioneered the development of several first in class drugs leading to regulatory approval, including the proteasome inhibitor bortezomib, the histone deacetylase (HDAC) inhibitors belinostat and vorinostat, and co-invented and led the international development of pralatrexate, which became the first drug approved for patients with relapsed or refractory peripheral T-cell lymphoma, now approved in over 35 countries around the world.

A past member of the Food and Drug Administration’s Oncology Drug Advisory Committee (ODAC), he has also successfully aided in filling New Drug Applications in China, Japan, and Taiwan, as well as the European Medicines Agency (EMA). He has held a number of prestigious leadership positions in the major cancer centers in New York City including Memorial Sloan Kettering Cancer Center, where he held a faculty position for a decade leading the Laboratory of Experimental Therapeutics for the Lymphoid Malignancies, and Chief of the Division of Hematology and Oncology, and Deputy Cancer Center Director at the New York University Medical Center prior to joining Columbia.

Dr. O’Connor has published over 200 articles in peer reviewed journals, books and book chapters and reviews on the management of lymphoma, in addition to being a member of several important advisory boards, including the Scientific Advisory Board for the Lymphoma Research Foundation.

He has received countless awards for his research, including being named to Americas Top Cancer Doctors, being named among the Top 50 Irish-Americans in Science and Medicine by the Irish government, and being inducted into the New Jersey Inventors Hall of Fame. He is also recipient of the American Cancer Society Research Professorship, the most prestigious honor bestowed by the Society.

Dr Angela Gillian is currently Head Of Medical Affairs and Responsible Person with A. Menarini Pharmaceuticals Ireland. Her previous experience encompasses the clinical trials and biotech industries both in Ireland and internationally.

Angela holds a degree in Biochemistry from Trinity College Dublin and a PhD from the University of Dundee in Scotland. She also has a Diploma in Quality Management. She joined the board in March 2023.

Dr Katarzyna Goljanek-Whysall is an Associate Professor at the University of Galway, and Irish Research Council Laureate and Vice Dean For Equality, Diversity and Inclusion

Dr Goljanek-Whysall obtained her PhD at the University of East Anglia, studying the role of microRNAs in skeletal muscle development.  She  continued my research at the University of East Anglia. In 2013 she moved to Institute of Ageing and Chronic Disease, Liverpool studying the role of epigenetic changes in sarcopenia and osteoarthritis development.  In her current position at the University of Galway she is studying the therapeutic potential of microRNAs and oxidised microRNAs against muscle loss during ageing and disease, such as cachexia and ALS. Her group is also investigating the impact of COVID-19 on long-term muscle wasting and frailty.